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Abstract Polymorphic variants at the interleukin-2 (IL2)
locus affect the risk of several autoimmune disorders. Our
aim was to evaluate the association of the four IL2
polymorphisms (rs6822844, rs6534349, rs2069762 and
rs3136534) with type 1 diabetes (T1D) in the Polish popu-
lation, and to correlate them with the serum interleukin-2
levels. 543 unrelated T1D patients and 706 healthy control
subjects were enrolled. The minor T allele at rs6822844 was
significantly less frequent in T1D compared to controls
(p = 0.002; OR 0.71; 95 % CI 0.571–0.880). Likewise, the
frequency of the TT genotype was decreased among the
affected individuals (p = 0.007). In healthy subjects, strati-
fication according to the rs6822844 genotype revealed sig-
nificant differences in circulating interleukin-2 (p = 0.037)
with the highest levels in TT protective genotypes. Three
other IL2 polymorphisms did not display significant differ-
ences in allele and genotype distribution. In conclusion, the
rs6822844 variant is associated with T1D and may play a
functional role, or reflect the influence of another causative
genetic variant in linkage disequilibrium.
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Introduction
Type 1 diabetes (T1D) results from selective destruction of
the insulin-secreting pancreatic beta cells by the autore-
active T lymphocytes. The disease onset is probably trig-
gered by unknown environmental factors (diet, infection)
superimposed on specific genetic background in suscepti-
ble individuals. To date several genetic loci have been
identified which may affect the immune function and
thereby contribute to T1D development. The strongest
effect was demonstrated for the HLA region (chromosome
6p21), but other genes involved in the immune response
also play a role [1]. The IL2 gene, which encodes inter-
leukin-2, a cytokine produced predominately by the acti-
vated CD4? and CD8? T cells in response to T cell
receptor (TCR) stimulation, was one of the strong func-
tional candidates. Plausible association of the IL2 gene
with diabetes was first suggested in non-obese diabetic
(NOD) mouse model, based on congenic mapping of the
Idd3 susceptibility locus [2]. Functional data revealed that
IL2 variants in NOD mice might affect the interleukin-2
production by antigen-specific T cells and predispose to
organ-specific autoimmunity [3]. These analyses were
followed by the first genome-wide association scan in
human T1D, which showed a moderate evidence of the
association with the IL2 region (4q27) [4]. Rs6534347, an
intronic variant of the nearby KIAA1109 gene, was
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identified by imputation and rs17388568, localized to an
intron in the adjacent TENR (ADAD1) gene, revealed the
strongest signal based on multilocus analysis [4]. Further
sequencing and genotyping of the IL2 region in T1D
cohorts revealed the associations with rs3136534,
rs6836189 and replicated an association with rs17388568,
however, due to extensive linkage disequilibrium (LD)
across this locus, the genuine causative variant could not be
determined [5].
Early on, interleukin-2 was mainly regarded as a core
cytokine in protective cell-mediated immunity, responsible
for the clonal expansion of the effector T cells. Nowadays its
major and non-redundant action is attributed to the develop-
ment and homeostasis of the regulatory CD4?CD25?
Foxp3? T (Treg) cells, which ensure the elimination of the
self-reactive T lymphocytes [6]. Interleukin-2-deficient mice
develop a lethal lymphoproliferative syndrome with massive
inflammatory lesions and detectable autoantibodies [7]. There
is increasing body of in vitro evidence to support the crucial
role of the IL2 signaling pathway in Treg cell function and
maintenance of self-tolerance [8]. Therefore, polymorphic
variants at the 4q27 locus, which might alter the IL2 expres-
sion, could consequently affect the work of the immune sys-
tem. Indeed, single nucleotide polymorphisms (SNPs) in this
region were found to be associated with systemic and organ-
specific autoimmune disorders, such as rheumatoid and
juvenile idiopathic arthritis, multiple sclerosis, psoriasis,
celiac disease, inflammatory bowel disease [9–15]. Allergic
conditions—IgE-mediated allergy, asthma and atopic der-
matitis—also displayed an association with the IL2 gene
variants [16]. Moreover, IL2 SNPs were linked with other
immune phenomena, such as measles vaccine-induced
immunity and the risk of graft-versus-host disease in patients
undergoing hematopoietic stem cell transplantation [17, 18].
However, despite the unequivocal association with other
autoimmune disorders and promising GWAS results, 4q27
locus has been rarely examined in the replication studies in
different T1D populations to date [9, 10, 19].
The aim of this study was to investigate the association of
selected polymorphic variants of the IL2 gene (rs6822844
G/T, rs6534349 A/G, rs2069762 G/T, and rs3136534 A/C)
with T1D in the Polish population. We also made an attempt
to correlate the genotyping results with serum levels of the
interleukin-2, which may represent an intermediate pheno-
type, directly affected by the genetic factors.
Materials and methods
Selection of investigated IL2 SNPs
The choice of investigated polymorphisms was based upon
previous reports showing their involvement in T1D and
other autoimmune disorders. Rs6822844, located between
the IL2 and the neighboring IL21 gene, was found to be
associated with celiac disease, inflammatory bowel disease,
psoriasis, juvenile idiopathic and rheumatoid arthritis [9–
13, 15]. Rs2060762, located upstream to the IL2 promoter
(at -330 site), was previously shown to associate with
autoimmune (multiple sclerosis, MS) and allergic condi-
tions [14, 16]. The choice of rs3136534 was supported by
the data from the first genome-wide association study in
T1D [5]. Finally, rs6534349 was selected as a tagger
(r2 [ 0.9) for two other IL2 SNPs, rs2069777 and
rs2069779, located in intron 2 and 3, respectively.
Genotyping
The studied cohort consisted of 543 unrelated T1D patients
(284 females, 259 males) and 706 healthy control subjects
(378 females, 328 males), from the local Polish population
of Caucasian origin. Patients were recruited at the
Department of Pediatric Diabetes and Obesity. Their mean
age (±SD) at disease onset was 8.6 ± 4.5 years. The
diagnosis of T1D was based upon World Health Organi-
zation criteria and all patients required lifetime insulin
substitution. Control samples for the genotyping were
obtained from healthy blood donors with negative history
of autoimmunity and no signs of autoimmune disorders,
recruited at the Regional Blood Transfusion Centre. Their
mean age was 38.1 ± 10.2 years.
Genomic DNA was extracted from the peripheral blood
using Gentra Puregene Blood Kit (Qiagen). Genotyping
was performed using the polymerase chain reaction fol-
lowed by restriction fragment length polymorphism ana-
lysis (PCR–RFLP) for SNPs rs6534349, rs2069762 and
rs3136534. All fragments were amplified in 30-ll PCR
reactions using primers designed with the help of Primer3
online tool, and manufactured by Oligo (Warsaw, Poland)
[20]. Primer sequences, PCR conditions, restriction
enzymes and fragments are presented in Table 1. Geno-
typing of the rs6822844 was performed by allelic dis-
crimination analysis using the 7900HT Real-Time PCR
System and Taqman assay (C_28983601_10), under the
conditions recommended by the manufacturer (Applied
Biosystems, Foster City, CA). All genotypes were con-
firmed in 5 % of samples by direct DNA sequencing with a
BigDye Terminator Cycle Sequencing Ready Reaction Kit
(ABI Prism 3730 Genetic Analyzer, Foster City, CA). The
samples of confirmed genotypes were run as controls in all
reactions and 10–12 % of samples were genotyped twice.
Serum interleukin-2 levels
Serum levels of interleukin-2 were determined in a sub-
group of 93 consecutive patients with newly diagnosed
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T1D (mean age 8.9 ± 4.7 years) and 84 age-matched
healthy individuals (mean age 8.4 ± 5.3). Samples were
collected on the 20–24th day after T1D diagnosis, when the
affected subjects reached metabolic homeostasis on insulin
substitution, and no signs of inflammation were detectable
(confirmed by a negative serum C-reactive protein). Con-
trol samples for serum interleukin comparisons were col-
lected from healthy children undergoing routine medical
checkup before prophylactic vaccinations. Sera were
obtained after overnight fast and stored at -70 C until
analyzed. The cytokine levels were evaluated by means of
an ELISA assay (Quantikine Human IL-2 Immunoassay,
R&D Systems, Inc. Minneapolis, MN). The detection limit
for interleukin-2 is less than 7 pg/ml and intra- and inter-
assay precision CV 2.0–4.3 and 3.7–5.0 %, respectively.
The study was approved by the Ethics Committee at
Poznan University of Medical Sciences, and informed
consent was obtained from all participants or from their
parents in case of minors.
Statistical analysis
Hardy–Weinberg equilibrium was tested for each studied SNP
using online calculator available at the Helmholtz Center
Munich website (http://ihg.gsf.de/cgi-bin/hw/hwa1.pl).
Patients and the control group were compared byv2 tests using
2 9 2 and 3 9 2 contingency tables of genotype and allele
counts, respectively. The differences were considered signif-
icant with a p value\0.05. A Bonferroni correction for mul-
tiple test (four independent SNPs) would require a
significance threshold of p \ 0.0125. Logistic regression was
used to determine the allelic odds ratios (ORs) and their 95 %
confidence intervals (95 % CI) in case–control comparisons.
The calculations were performed using SPSS 18.0 software
(SPSS Inc., Chicago, IL). Linkage disequilibrium (LD) mea-
sures (r2) between investigated IL2 markers were assessed
with Haploview v.4.1 [21]. The power of the study to detect an
association was calculated with the PS Power and Sample Size
calculator v.2.1.30 (http://www.mc.vanderbilt.edu/prevmed/
ps). Assuming an OR of 0.64, the power of the present study to
detect an effect in the T1D cohort was 98 % for rs6822844 [9].
The power to reproduce an OR of 1.54 previously reported for
rs2069762 in MS was 92 % [22], and to replicate an OR of
1.11 found for rs3136534 in T1D–only 31 % [5, 9].
Serum levels of interleukin-2 are presented as
mean ± standard deviation (±SD) in case of a normal data
distribution or as median with their range when the dis-
tribution was not normal. Kolmogorov–Smirnov test was
used to check for the data normality. Normally distributed
interleukin-2 levels in patients and controls were compared
using unpaired Student’s t test, while genotype-stratified
subgroups displayed non-normal data distribution and
hence were analysed by Kruskal–Wallis test. Two-tailed
p values \ 0.05 were considered statistically significant.
Results
Genotyping
No SNP displayed a significant departure from Hardy–
Weinberg equilibrium in the patient and control cohorts
(p C 0.074).
The minor T allele at the rs6822844 locus was found in
14.2 % (154 of 1,085) T1D alleles compared to its 18.9 %
prevalence (267 of 1,412 alleles) in healthy controls
(p = 0.002), yielding a protective OR of 0.71 (95 % CI
0.571–0.880). In line, the frequency of the TT genotype was
significantly lower among affected subjects vs. controls
(p = 0.007) (Table 2). Both associations survived after
correction for multiple testing (4 tests, corrected p-values
0.008 and 0.028, respectively). The other three SNPs:
rs6534349, rs2069762, and rs3136534, did not present sig-
nificant associations in these investigated groups (complete
allele and genotype data displayed in Table 2). Linkage
disequilibrium measurements revealed very low pairwise r2
values between rs6822844 and other IL2 SNPs, ranging
from 0.01 (rs6822844–rs6534349) to 0.09 (rs6822844–
Table 1 Primer sequences, PCR conditions and restriction enzymes used for genotyping of the IL2 SNPs: rs6534349, rs2069762, rs3136534








rs6534349 A/G F: 50CCTACTGTTTCTAGTTACTG 437 49 C BstNI (MvaI) Allele A: 84 ? 353
R: 50AGATTGGGACTATAAGACTG Allele G: 84 ? 153 ? 200
rs2069762 T/G F:50ATTCACATGTTCAGTGTAGTTCTA 229 50 C BfaI (FspBI) Allele T: 229
R: 50TCCTCTTCTGATGACTCTTTG Allele G: 22 ? 207
rs3136534 A/C F: 50GCCAAGGCTCTAGGTGAACA 359 57 C PsuI (BstYI) Allele A: 359
R: 50CAAGCTCTGCCTACCAGGTT Allele C: 87 ? 272
The forward primer of the rs2069762 was modified (T?C) in order to include a BfaI restriction site
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rs3136534). Similar LD results were derived from the
HapMap CEU genotype data. Therefore, the haplotype
analysis was not performed, as the study of the inferred
haplotypes would not add any further information.
Serum interleukin-2 levels
Serum interleukin-2 levels in T1D patients were lower
compared to controls however, the difference did not reach
statistical significance (8.80 ± 4.95 vs. 10.66 ± 5.42 pg/
ml, p = 0.066). Stratification of the control samples
according to the rs6822844 genotype revealed significant
difference in the interleukin-2 concentration: median 7.94
(range 0.07–17.52) pg/ml for GG, 9.28 (5.25–18.66) pg/ml
for GT and 13.80 (6.82–20.83) pg/ml for TT (p = 0.037).
On the contrary, circulating interleukin-2 levels in T1D
patients were similar in carriers of different rs6822844
genotypes (p = 0.358) (Table 3).
Discussion
The current study indicates an association between
rs6822844 polymorphism and T1D in the Polish popula-
tion. In our analysis, the minor T allele appeared protec-
tive, with only 2.9 % of T1D patients carrying the TT
genotype compared to 4.1 % of healthy controls. These
results confirm formerly published data from the Dutch and
Columbian T1D cohorts [9, 10]. On the contrary, in a study
of genetic variants shared between T1D and celiac disease,
rs6822844 did not reach the threshold of statistical signif-
icance in a large British T1D cohort [23]. Likewise, a
recent analysis among Spanish T1D subjects revealed only
a trend for significance at this SNP [19]. These discrep-
ancies may arise from the population differences, or lim-
ited sample size, which might be insufficient to detect a
modest effect. However, the direction of this association,
with a protective T allele and a major G allele being a risk
Table 2 Distribution of the IL2
genotypes and alleles in Polish
patients with type 1 diabetes
(T1D) and controls
P values in bold indicate
statistically significant results
IL2 SNP Genotype Allele T1D patients Controls Uncorrected
p valuen = 543 (%) n = 706 (%)
rs6822844 G/T GG 405 (74.6) 468 (66.3) 0.007
GT 122 (22.5) 209 (29.6)
TT 16 (2.9) 20 (4.1)
G 932 (85.8) 1,145 (81.1) 0.002
T 154 (14.2) 267 (18.9)
rs6534349 A/G AA 440 (81.0) 578 (81.9) 0.562
AG 97 (17.9) 124 (17.5)
GG 6 (1.1) 4 (0.6)
A 977 (90.0) 1,280 (90.7) 0.564
G 109 (10.0) 132 (9.3)
rs2069762 G/T TT 273 (50.2) 339 (48.0) 0.604
GT 217 (40.0) 302 (42.8)
GG 53 (9.8) 64 (9.2)
T 763 (70.3) 980 (69.4) 0.646
G 323 (29.7) 432 (30.6)
rs3136534 A/C AA 225 (41.4) 281 (39.8) 0.840
AC 259 (47.7) 345 (48.9)
CC 59 (10.9) 80 (11.3)
A 709 (65.3) 907 (64.2) 0.586
C 377 (34.7) 505 (35.8)
Table 3 Serum levels of interleukin-2 in patients with type 1 diabetes (T1D) and in healthy control subjects stratified according to the rs6822844
genotype
Interleukin-2 (pg/ml) rs6822844 genotype p-value
GG GT TT
T1D patients 10.07 (0.07–20.83) 11.60 (4.48–17.90) 12.19 (5.60–19.67) 0.358
Controls 7.94 (0.07–17.52) 9.28 (5.25–18.66) 13.80 (6.82–20.83) 0.037
Interleukin values represent medians (range), and p values refer to nonparametric Kruskal–Wallis test comparing genotype-stratified subgroups
P values in bold indicate statistically significant results
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factor, is common to other autoimmune phenotypes, com-
prising celiac disease, ulcerative colitis, juvenile idiopathic
and rheumatoid arthritis [9, 11–13]. Previous and current
findings provide ample evidence for the 4q27 region as a
general autoimmunity locus. This 480 kb region harbors
four genes: KIAA1109–TENR–IL2–IL21. KIAA1109 is
highly expressed in ovaries and brain, TENR expression is
testis-specific, whereas IL2 and IL21 encode interleukins,
which are both functional candidates in autoimmune dia-
betes. Interleukin-21 is another T cell-derived cytokine,
which enhances the proliferation and effector role of
CD8? T lymphocytes, and is required for generating an
inflammatory Th17 response [24]. Priming with interleu-
kin-21 enables autoreactive CD8? T cells to respond to
weak antigens and may induce the diabetes onset in sus-
ceptible NOD mice [25].
Rs6822844 is a noncoding SNP, located downstream to
the IL2 and approximately 24 kb 50 of the IL21 gene. Based
on sequence homology, it was suggested that the rs6822844-
carrying fragment might encode a micro-RNA precursor
[10]. A substitution of the conserved G allele by the minor T
variant could hamper miRNA synthesis, and consequently
influence the expression of other genes. In fact, the true role
of this SNP remains to be characterized. One may not
exclude that a genuine causal variant, which affects the
immune function and contributes to autoimmunity, is loca-
ted elsewhere within a cluster of several SNPs in the 4q27
region. Rs6822844 was reported as a perfect proxy for the
five-SNP haplotype (comprising rs4505484, rs11732095,
rs6822844, rs4492018 and rs1398553) that is most associ-
ated with autoimmune disease [9]. In contrast, LD between
rs6822844 and another T1D-associated SNP, rs17388568, is
low (r2 = 0.09) hence both variants might exert an inde-
pendent effect. However, localization of rs17388568 in
intron 8 of the TENR gene makes its direct influence on
immune system rather unlikely.
We did not find any association with three other studied
SNPs. Our analysis was underpowered to reliably detect an
effect of rs3136534. In contrast, the power of this study
was adequate to investigate rs2069762, a polymorphic
variant consistently associated with MS [22]. Although
T1D and MS are both autoimmune conditions, disturbances
of different immune pathways might prevail in their
development. For instance, distinct causal SNPs in the
4q27 locus could affect the expression of IL2 and IL21. On
the other hand, if susceptibility variants located within the
same locus do not overlap, this may reflect the causative
role of yet another SNP, which remains in LD. To elucidate
this matter, the region should be thoroughly resequenced
and further genotyped in large cohorts in order to identify
most plausible SNPs for functional analyses.
Interleukin-2 plays a key role in thymic differentiation
and peripheral expansion of CD4 ? CD25 ? Tregs.
Polymorphic variants of the genes encoding interleukin-2
and its receptor subunits might enhance/impair their
expression and therefore affect the activity of the IL2
signaling pathway. This in turn could influence the function
of the CD4?CD25? Tregs and eventually, promote the
development of autoimmune disorders. In fact, SNPs
located within the extended murine IL2 promoter, which
associate with autoimmune disease, were found to alter the
gene transcription in CD4? T cells [26] and diminished
interleukin-2 synthesis was reported for a susceptible
haplotype in NOD mice [3]. In humans, the presence of an
autoimmunity-associated IL2RA haplotype correlates with
reduced interleukin-2 responsiveness in stimulated CD4?
T cells and decreased ability of Tregs to suppress the
proliferation of autologous effector T cells [8].
In our study we limited the analysis to serum levels of
interleukin-2 in patients and controls, and thereafter we
stratified the results according to IL2 genotype. Interleukin-
2 is a cardinal regulatory cytokine in the immune system,
but its pleiotropic role may impair reliable distinction of
the genuine effects from secondary changes related with
the disease. This is the most likely reason of major
inconsistencies between former studies, which revealed
various interleukin-2 levels among T1D subjects compared
to healthy controls [27–29]. A trend for lower circulating
interleukin-2 in T1D was found in our study. This obser-
vation remains in line with most previous analyses and is
also corroborated by the results of the peripheral blood
mononuclear cell ex vivo cultures [27, 28, 30–32]. How-
ever, the experiments, which investigated in vitro synthesis
of the interleukin-2 in a longitudinal way, indicate that its
peak was similar but considerably delayed in T1D subjects
compared to controls [33]. These observations support a
hypothesis of impaired interleukin-2 secretory pattern
among patients with T1D. Of note, the interleukin-2 pro-
duction by the T1D lymphocytes appears independent of
the degree of the metabolic control, and is probably regu-
lated at a pretranslational stage [30, 31]. Moreover,
decreased serum interleukin-2 concentrations were also
reported in diabetic patients with long-lasting disease,
when the active autoimmune reaction has been attenuated
[28]. Therefore, at least partial modulation of the inter-
leukin-2 synthesis could be attributed to genetic factors
[32]. Former analyses revealed an association between
serum cytokine levels and a polymorphic variant upstream
to the IL2 gene promoter (-330 T/G, rs2060762) assessed
in MS and in neuroendocrine tumors [14, 34]. Although its
position makes rs2060762 a plausible functional candidate,
we were not able to confirm this correlation in our cohort
(data not shown, p [ 0.05). Instead, significant difference
in circulating interleukin-2 was found among healthy car-
riers of three rs6822844 genotypes, and the lowest cytokine
levels were present in subjects with the T1D risk GG
Mol Biol Rep (2013) 40:6957–6963 6961
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genotype (Table 3). However, the statistical significance of
this finding is borderline. Additionally, this relation was no
more significant when evaluated among T1D subjects
(p = 0.358), possibly due to overlying immune phenomena
connected with the recent disease onset. Replication studies
in larger cohorts, as well as experimental investigation of
the IL2 gene expression at the mRNA level would be
mandatory to confirm these findings. Considering the
location of the rs6822844 with regard to the IL2 gene, this
SNP seems rather unlikely regulator of the gene expres-
sion, however, another unidentified polymorphism in LD
may directly affect IL2 regulation. Gene expression usually
undergoes complex, multifactorial influence, but similar
genotype-intermediate phenotype relationship was reported
for the IL2RA gene, which encodes high-affinity alpha
subunit of the interleukin-2 receptor (CD25 molecule). Its
polymorphic variants are strongly associated with T1D and
affect the soluble receptor levels, although discrepancies in
the effect of the IL2RA genotype on serum measurements
were detected in different autoimmune conditions [35].
In conclusion, the present study confirms the association
of the rs6822844 with T1D in another Caucasian popula-
tion. Furthermore, genotype-related differences in serum
interleukin-2 levels suggest plausible functional role of this
polymorphism. However, other nearby SNPs, which
remain in LD with rs6822844, may play the true causative
role. Further functional studies are essential to dissect
downstream effects of the molecular variants at this locus
and the mechanisms of their contribution to increased risk
for T1D and other autoimmune pathology.
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